The HHS peptide notice, explained: what it says and what it does not

What did HHS announce on 30 October 2026?

HHS published a notice of availability in the Federal Register, 91 FR 68526 (document number 2026-22192, RIN 0910-ZD94), for a draft "Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances". The notice is signed for the Secretary of HHS, not by FDA. We read the notice through the Federal Register API and its full text.

• In the notice's words, HHS "does not intend to take enforcement action" against a state-licensed pharmacy, federal facility or licensed physician compounding with a peptide bulk drug substance found in its Appendix A.
• HHS gives a reason: it believes there is significant interest in these peptides in compounding "given the lack of availability of approved products".
• The notice also states that compounded drugs are not FDA-approved, so FDA does not review their safety, effectiveness or quality before they are marketed. It says they "may pose risks to patients".

What is this notice not?

• The HHS notice is not an FDA approval. The notice itself says compounded drugs are not FDA-approved, and nothing in it approves a peptide for any use.
• It is not the 503A bulks list. The notice says that list is "developed through rulemaking" and that FDA's future rulemakings "may propose adding some or all of these peptides" to it.
• It is not binding. The notice says the draft "does not establish any rights for any person and is not binding on HHS or the public".

Who does it cover, and for how long?

The notice names three groups: a state-licensed pharmacy, a federal facility and a licensed physician. The policy applies while FDA develops the 503A bulks list through rulemaking, which the notice does not give a date for.

HHS says it may revisit the policy, in whole or in part, "if, among other things, a safety signal or product quality issue arises" with a compounded product in scope. The notice does not say what would count as a signal.

Which peptides are covered?

We do not know from the primary text. The notice points to an appendix, and the HHS file it links is the appendix HHS links, which we could not open because the site blocks scripts. Treat every peptide name below as secondary.

Press reports from AJMC and BioSpace (both secondary) say six peptides are covered, including BPC-157. One report names TB-500, epitalon, MOTS-c, KPV and semax as the others, and that list may differ from the appendix.

How does it relate to FDA's own page?

FDA's safety-risks page (content current as of 22 April 2026) has a Category 2 table with 14 rows and a "nominated but withdrawn" table with 17 rows. We counted them from our parsed copy, and the withdrawn table includes BPC-157, CJC-1295, Epitalon, GHK-Cu (injectable routes), Melanotan II, Selank, Semax, and TB-500.

That page predates the HHS notice by six months, and the notice comes from a different part of government. The withdrawn table records that nominators withdrew those substances, and it is not a ruling on safety. We explain the categories in how FDA's peptide categories work.

On 23 July 2026 FDA's advisory committee voted 8 to 6 on BPC-157, per ABC News and Time, both secondary. A vote advises FDA and decides nothing. Our BPC-157 check covers that vote.

When do comments close?

The Federal Register's own record of the docket lists a comment end date of 14 November 2026, and the docket was open for comment when we read it. The notice text says written comments can be submitted "until 2 weeks after date of publication" through regulations.gov on docket HHS-OASH-2026-0496, which is consistent with that date. Check the docket for the exact day before relying on it.

We could not load the regulations.gov docket page from a script (it returned HTTP 403), so the docket record above is the Federal Register's copy. That record showed zero comments when we read it on 30 October 2026.

What does it change about the evidence?

Nothing. The notice is about enforcement, not data, and it cites no new studies. A PubMed search for BPC-157 still returns 226 papers, and 0 are tagged as a clinical or randomized trial (query: ("BPC-157"[tiab] OR "BPC 157"[tiab] OR "Body Protection Compound-157"[tiab]), read 30 October 2026).

Missing trials mean missing evidence, not proof of harm or of benefit. For where this sits among topics with real trial depth, see the evidence ladder, and for a compound with many trials that FDA still lists in Category 2, see the MK-677 check.

1. Find the primary document and read its own words. A headline is a summary, and summaries go stale.
2. Ask what kind of document it is: an approval, a list, a draft policy, or a guidance. They bind differently.
3. Check whether the document is binding. This one says it is not.
4. Note the dates: when it was published, when comments close, when the source page was last current.
5. Take what you read to a licensed clinician.

What should you do with this?

• If you saw a headlineRead the primary noticeIt is two pages in the Federal Register as 91 FR 68526. It is a draft, non-binding and not an approval.
• If you want the current statusCheck FDA's page and its dateThe safety-risks page said "current as of 22 April 2026" when we read it. The HHS notice does not change that page.
• If this touches your own healthTalk to a licensed clinicianA policy about enforcement says nothing about whether a product is right for you. We give no dosing, sourcing or treatment advice.

How these facts were read

FAQ

Bottom line

HHS published a draft, non-binding policy on 30 October 2026 that is about enforcement, not approval and not evidence. We read the notice but not its appendix, so the peptide list stays press-reported until we can open it. Take any decision about your own health to a licensed clinician.